Charalambous, Thalis http://orcid.org/0000-0002-6919-4486
Clayden, Jonathan D.
Powell, Elizabeth
Prados, Ferran http://orcid.org/0000-0002-7872-0142
Tur, Carmen http://orcid.org/0000-0003-1849-3184
Kanber, Baris http://orcid.org/0000-0003-2443-8800
Chard, Declan
Ourselin, Sebastien
Wheeler-Kingshott, Claudia A. M. Gandini
Thompson, Alan J. http://orcid.org/0000-0002-4333-8496
Toosy, Ahmed T.
Article History
Received: 28 October 2019
Accepted: 13 February 2020
First Online: 27 February 2020
Competing interests
: Thalis Charalambous has nothing to disclose. Jonathan D. Clayden has nothing to disclose. Elizabeth Powell has nothing to disclose. Ferran Prados is non-clinical Guarantors of Brain fellow. He has also received honoraria from Bioclinica Inc. Carmen Tur has received an ECTRIMS post-doctoral research fellowship in 2015. She has also received honoraria and support for travelling from Bayer-Schering, Teva, Merck-Serono and Serono Foundation, Biogen, Sanofi-Aventis, Novartis, and Ismar Healthcare. Baris Kanber has nothing to disclose. Declan Chard has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences and Teva; and has previously held stock in GlaxoSmithKline. Sebastien Ourselin has nothing to disclose. Claudia A.M. Gandini Wheeler-Kingshott has nothing to disclose. Alan J. Thompson received honoraria/support for travel for consultancy from Eisai, Excemed, MedDay, support for travel from the International Progressive MS Alliance and National MS Society (USA), and an honorarium from SAGE Publishers as Editor-in-Chief of MSJ. Ahmed T. Toosy has received speaker honoraria from Biomedia, Sereno Symposia International Foundation, Bayer and meeting expenses from Biogen Idec and Novartis and is the UK PI for two clinical trials sponsored by MEDDAY pharmaceutical company (MD1003 in optic neuropathy [MS-ON] and progressive MS [MS-SPI2]).